

Genialis, Oncologie to use precision medicine for gastric cancer

23 January 2020 | News

To refine patient stratification methodologies



US based Genialis, a leader in applied data science for the development of precision medicines, has announced a collaborative partnership with US and China based Oncologie, an international, clinical-stage biopharma developing next-generation immunotherapies for cancer.

Initial activities will focus on the use of Genialis' *Expressions* software platform and analytics IP with Oncologie's clinical and translational expertise to refine patient stratification methodologies.

Early work between the two companies has thus far focused on modeling gene expression signatures predictive of treatment for gastric cancer. The patent-pending enhanced methodology will further Oncologie's clinical development plans to expand beyond gastric cancer to other tumor microenvironment phenotypes.